Abstract 471TiP
Background
Neurokinin-1 (NK-1) receptor antagonists will prevent CINV effectively but are not affordable for patients of low socioeconomic status and there is still an unmet need for the prevention of CINV in the low socio-economic setting. Recent studies show olanzapine which blocks multiple neurotransmitters in the brain is also effective in preventing CINV and pregabalin which inhibits the release of neurotransmitters is effective in preventing postoperative nausea and vomiting. A mechanistic synergism is expected between the olanzapine and pregabalin combination. Therefore, this trial was designed to evaluate the add-on combination of olanzapine and pregabalin in the management of CINV.
Trial design
This trial is a group sequential response adaptive randomized double-blinded clinical trial. The O'Brien-Fleming boundaries were defined for efficacy and futility. The total sample size to achieve the primary objective of the difference in the proportion of patients with “overall no nausea” was calculated to be 84, with an allocation ratio of 1:1. Depending on the results of each interim analysis, the allocation ratio will be changed, and more patients will be allocated to the well-performing arm. In our study, we enrolled cancer patients belonging to low socio-economic status who planned to receive highly emetogenic cancer chemotherapeutic agents and the standard of care antiemetic premedication (ondansetron 8mg and dexamethasone 8mg). Patients received either olanzapine 5 mg plus pregabalin 75 mg orally or a matching placebo daily on day 1 through day 5 in addition to their standard antiemetic premeditations. In stage one of the trial, 30 patients were equally randomized into two groups and the interim analysis showed the experimental group performed better in terms of “overall no nausea” (40% vs. 6.6 % p value-0.042). However, it didn't breach the boundary (0.0035) fixed by the O'Brien and Fleming approach. So, the trial is being continued to the second stage. As the Z (1.73) value was between 1.5-2, the allocation ratio has been changed to 2:1 for the next stage of the trial as per the protocol.
Clinical trial identification
CTRI/2021/08/035451.
Legal entity responsible for the study
The authors.
Funding
Indian Council of Medical Research (ICMR), India.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
16P - Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Presenter: Jiun-I Lai
Session: Poster Display
Resources:
Abstract
17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast canceR (screening/ stage shifting) utilizing Integrated MobilE Clinics and pAtient Reported online Evaluations and Education
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
18P - Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Presenter: Anitha Ramesh
Session: Poster Display
Resources:
Abstract
19P - Referral patterns among breast cancer patients in county-level hospitals in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
20P - Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date
Presenter: Daniëlle Verschoor
Session: Poster Display
Resources:
Abstract
22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Presenter: HEAMANTHAA Padmanabhan
Session: Poster Display
Resources:
Abstract
23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Presenter: Soo Chin Lee
Session: Poster Display
Resources:
Abstract
24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia
Presenter: Vivian Lee
Session: Poster Display
Resources:
Abstract
25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
Presenter: Bo-Fang Chen
Session: Poster Display
Resources:
Abstract